- Home
- SPH vs AGIO Comparison
SPH vs AGIO Comparison
Compare SPH & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPH
- AGIO
- Stock Information
- Founded
- SPH 1945
- AGIO 2007
- Country
- SPH United States
- AGIO United States
- Employees
- SPH N/A
- AGIO N/A
- Industry
- SPH Other Specialty Stores
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- SPH Consumer Discretionary
- AGIO Health Care
- Exchange
- SPH Nasdaq
- AGIO Nasdaq
- Market Cap
- SPH 1.2B
- AGIO 1.4B
- IPO Year
- SPH 1996
- AGIO 2013
- Fundamental
- Price
- SPH $18.63
- AGIO $33.81
- Analyst Decision
- SPH Sell
- AGIO Buy
- Analyst Count
- SPH 1
- AGIO 6
- Target Price
- SPH $17.00
- AGIO $58.60
- AVG Volume (30 Days)
- SPH 214.3K
- AGIO 602.3K
- Earning Date
- SPH 08-07-2025
- AGIO 07-31-2025
- Dividend Yield
- SPH 6.95%
- AGIO N/A
- EPS Growth
- SPH N/A
- AGIO N/A
- EPS
- SPH 1.46
- AGIO 11.45
- Revenue
- SPH $1,424,243,000.00
- AGIO $37,035,000.00
- Revenue This Year
- SPH $10.99
- AGIO $22.30
- Revenue Next Year
- SPH N/A
- AGIO $219.19
- P/E Ratio
- SPH $12.97
- AGIO $2.92
- Revenue Growth
- SPH 4.02
- AGIO 25.96
- 52 Week Low
- SPH $15.20
- AGIO $23.42
- 52 Week High
- SPH $22.24
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- SPH 47.76
- AGIO 54.35
- Support Level
- SPH $18.00
- AGIO $32.53
- Resistance Level
- SPH $19.40
- AGIO $35.88
- Average True Range (ATR)
- SPH 0.53
- AGIO 1.30
- MACD
- SPH 0.06
- AGIO -0.29
- Stochastic Oscillator
- SPH 56.50
- AGIO 29.27
About SPH Suburban Propane Partners L.P.
Suburban Propane Partners LP distributes propane, fuel oil, and other refined fuels to customers in the East Coast and West Coast regions of the United States. Other operations include natural gas and electricity marketing in the deregulated New York and Pennsylvania markets. The company operates in three segments: Propane; Fuel Oil and Refined Fuels; and Natural Gas and Electricity. It generates maximum revenue from Propane segment.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.